GlassScriptPhysician profile
Rajesh Nahar
NPI 1184640328
$3,316.65
in general payments reported to CMS, 2019-2025
19 companies · $17.53 in 2025
The $17.53 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,754 · 2021: $367 · 2022: $145 · 2023: $33.10 · 2025: $17.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $50.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $50.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,327.22 | 2019 | |
| Genzyme Corporation | $350.00 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $180.40 | 2021-2023 | Imbruvica |
| Janssen Biotech, INC. | $81.56 | 2019 | |
| Amgen INC. | $71.93 | 2019 | |
| Genentech USA, INC. | $57.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $41.29 | 2019 | |
| Merck Sharp & Dohme LLC | $28.96 | 2019 | |
| Gilead Sciences, INC. | $26.67 | 2019 | |
| Lilly USA, LLC | $25.94 | 2019 | |
| Karyopharm Therapeutics INC. | $17.53 | 2025 | Xpovio |
| Daiichi Sankyo INC. | $15.36 | 2019 | |
| Beigene USA, INC. | $14.71 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.48 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.46 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $12.88 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.80 | 2019 | |
| Taiho Oncology, INC. | $12.07 | 2019 | |
| Astellas Pharma US INC | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Nahar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.